Trial Profile

A Phase 1, Open-label, Dose Escalation and Dose Expansion Study, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521 Monotherapy and Combination Therapies in Participants With Clear Cell Renal Cell Carcinoma and Other Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 04 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cabozantinib (Primary) ; Casdatifan (Primary) ; Volrustomig (Primary) ; Zimberelimab (Primary)
Indications Renal cell carcinoma; Solid tumours
Focus Adverse reactions
Acronyms ARC-20; eVOLVE
Sponsors Arcus Biosciences

27 Feb 2026 Protocol has been amended to include two new arms (Experimental: Dose Expansion Cohort 9 and Experimental: Dose Expansion Cohort 10) , it has changed from 13 to 15.
27 Feb 2026 Planned number of patients changed from 302 to 362.
27 Feb 2026 Planned End Date changed from 1 Jul 2027 to 1 Mar 2029.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com